modelImiquimod
Extends from Pharmacolibrary.Drugs.ATC.D.D06BB10.
Information
| name: | Imiquimod | |
| ATC code: | D06BB10 | route: | topical |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 140 | L |
| clearance: | 50 | L/h |
| other parameters in model implementation | ||
Imiquimod is an immune response modifier used topically for the treatment of various dermatological conditions such as actinic keratosis, superficial basal cell carcinoma, and external genital warts. It is approved and widely used in clinical practice for these indications.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult humans following topical administration, as clinical absorption is minimal and most studies report limited systemic exposure.
References
Garcia-Mouronte, E, et al., & Bea-Ardebol, S (2023). Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer. International journal of molecular sciences 24(13) –. DOI:10.3390/ijms241310835 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37446011
Dai, X, et al., & Donnelly, RF (2024). Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Molecular pharmaceutics 21(6) 2813–2827. DOI:10.1021/acs.molpharmaceut.3c01223 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38752564
Lotlikar, VB, et al., & Londhe, VY (2025). Unlocking relief: formulation, characterization, and in vivo assessment of salicylic acid-loaded microemulgel for psoriasis management. Naunyn-Schmiedeberg's archives of pharmacology 398(3) 3037–3047. DOI:10.1007/s00210-024-03447-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39325151
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)